What we are studying

The main purpose of this clinical trial is to determine whether treating anal high-grade squamous intraepithelial lesions (HSIL) is effective in reducing the incidence of anal cancer in HIV-infected men and women.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 35+

Eligibility Criteria

  • HIV positive

What is involved

  • Visits to the clinic every 3-6 months until study completion
  • Blood draws
  • High resolution anoscopy
  • Pregnancy tests
  • Questionnaires


$100 for every completed study visit when HRA is performed. $25 for study visits when only swabs are collected.

Contact Information

Study Coordinator
Tamantha Miller

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.